Dagmara Klasa-Mazurkiewicz

Author

Also Known As

D Klasa-Mazurkiewicz, D. KLASA-MAZURKIEWICZ, D. Klasa-Mazurkiewicz, D. Klasa–Mazurkiewicz, DAGMARA KLASA‐MAZURKIEWICZ, Dagmara Klasa-Mazurkiewicz, Jalid Sehouli, Vlad Alexandru Gata, Wieslawa Bednarek

Publications

900

Citations

H-Index

Concepts

All Affiliations

Gdańsk Medical University Yonsei University University of Gdańsk

About

Dagmara Klasa-Mazurkiewicz is an author at Gdańsk Medical University specializing in medicine, obstetrics, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	196
2	Obstetrics	5	5	196
3	Pathology	3	3	137
4	Endocrinology	1	1	48
5	Pharmacology	1	1	48

Dagmara Klasa-Mazurkiewicz

Publications

238

Citations

H-Index

Page 1

	Year	Citations
Changes in mRNA and protein levels of human HtrA1, HtrA2 and HtrA3 in ovarian cancer Joanna Narkiewicz, Dagmara Klasa-Mazurkiewicz, Dorota Żurawa‐Janicka, Clinical Biochemistry Endocrine-related CancerOncogenic AgentMedicineProtein LevelsGynecology	2008	71
Continuous, daily levonorgestrel/ethinyl estradiol vs. 21-day, cyclic levonorgestrel/ethinyl estradiol: efficacy, safety and bleeding in a randomized, open-label trial A. Teíchmann, Dan Apter, Janusz Emerich, Contraception Open-label TrialHormonal ContraceptiveDaily Levonorgestrel/ethinyl EstradiolMedicineGynecology	2009	48
Clinical significance of VEGFR-2 and VEGFR-3 expression in ovarian cancer patients. Dagmara Klasa-Mazurkiewicz, Mirosław Jarząb, Tomasz Milczek, PubMed PathologyGynecologyVegfr-3 Tissue ExpressionCancer BiologyTumor Biology	2011	43
Maspin overexpression correlates with positive response to primary chemotherapy in ovarian cancer patients Dagmara Klasa-Mazurkiewicz, Joanna Narkiewicz, Tomasz Milczek, Gynecologic Oncology Endocrine-related CancerMedicineGynecologyPathologyPrimary Chemotherapy	2009	23
Selective gene expression profiling of mTOR-associated tumor suppressor and oncogenes in ovarian cancer Piotr Laudański, Oksana Kowalczuk, Dagmara Klasa-Mazurkiewicz, Folia Histochemica et Cytobiologica	2011	14
Prediction Model for Bronchopulmonary Dysplasia in Preterm Newborns Joanna Jassem-Bobowicz, Dagmara Klasa-Mazurkiewicz, Anton Żawrocki, Children	2021	14
Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial Toon Van Gorp, Kathleen Moore, Gottfried E. Konecny, The Lancet Oncology	2025	14
LBA41 Durvalumab (durva) plus carboplatin/paclitaxel (CP) followed by maintenance (mtx) durva ± olaparib (ola) as a first-line (1L) treatment for newly diagnosed advanced or recurrent endometrial cancer (EC): Results from the phase III DUO-E/GOG-3041/ENGOT-EN10 trial Shannon N. Westin, Kathleen N. Moore, Hye Sook Chon, Annals of Oncology MedicineCancer ManagementGynecologyRecurrent Endometrial CancerLba41 Durvalumab	2023	11

Page 1